Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market

Author： Bruce R. Douglas   Govindasamy Sumathi   Sylla Laurie   Kamarulzaman Adeeba   Altice Frederick  

Publisher： Informa Healthcare

ISSN： 0095-2990

Source： The American Journal of Drug and Alcohol Abuse, Vol.35, Iss.2, 2009-03, pp. : 68-72

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Buprenorphine/naloxone reduces drug abuse, costs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 552, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†

By Orman Jennifer S.   Keating Gillian M.  

CNS Drugs, Vol. 23, Iss. 10, 2009-10 ,pp. : 899-902

Adis International

Access to resources Recommend Favorite

Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review

By  

Current Drug Abuse Reviews, Vol. 4, Iss. 1, 2011-03 ,pp. : 28-41

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment

By Douglas Bruce R.  

The American Journal of Drug and Alcohol Abuse, Vol. 39, Iss. 2, 2013-03 ,pp. : 80-85

Informa Healthcare

Access to resources Recommend Favorite

Buprenorphine and Naloxone Combinations and Dopamine

By  

Current Psychopharmacology, Vol. 6, Iss. 2, 2018-01 ,pp. : 111-121

Bentham Science Publishers

Access to resources Recommend Favorite